Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

[Diagnostics and treatment of tuberculosis under immunotherapy for multiple sclerosis : Current status and recommendations in Germany].

Bittner S, Engel S, Lange C, Weber MS, Haghikia A, Luessi F, Korn T, Klotz L, Bayas A, Paul F, Heesen C, Stangel M, Wildemann B, Bergh FT, Tackenberg B, Trebst C, Warnke C, Linker R, Kerschensteiner M, Zettl U, Tumani H, Brück W, Meuth SG, Kümpfel T, Hemmer B, Wiendl H, Gold R, Zipp F.

Nervenarzt. 2019 Jul 11. doi: 10.1007/s00115-019-0760-0. [Epub ahead of print] Review. German.

PMID:
31297574
2.

Thymoma-Associated Paraneoplastic Autoimmune Multiorgan Syndrome-From Pemphigus to Lichenoid Dermatitis.

Solimani F, Maglie R, Pollmann R, Schmidt T, Schmidt A, Ishii N, Tackenberg B, Kirschbaum A, Didona D, Pickert J, Eming R, Hashimoto T, Hertl M.

Front Immunol. 2019 Jun 21;10:1413. doi: 10.3389/fimmu.2019.01413. eCollection 2019.

PMID:
31293579
Free PMC Article
3.

Association of Intrathecal Immunoglobulin G Synthesis With Disability Worsening in Multiple Sclerosis.

Gasperi C, Salmen A, Antony G, Bayas A, Heesen C, Kümpfel T, Linker RA, Paul F, Stangel M, Tackenberg B, Bergh FT, Warnke C, Weber F, Wiendl H, Wildemann B, Zettl UK, Ziemann U, Zipp F, Tumani H, Gold R, Hemmer B; German Competence Network of Multiple Sclerosis.

JAMA Neurol. 2019 Apr 29. doi: 10.1001/jamaneurol.2019.0905. [Epub ahead of print]

PMID:
31034002
4.

Real-world persistence and benefit-risk profile of fingolimod over 36 months in Germany.

Ziemssen T, Lang M, Tackenberg B, Schmidt S, Albrecht H, Klotz L, Haas J, Lassek C, Couto CA, Findlay JA, Cornelissen C; PANGAEA study group.

Neurol Neuroimmunol Neuroinflamm. 2019 Mar 7;6(3):e548. doi: 10.1212/NXI.0000000000000548. eCollection 2019 May.

5.

Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies.

Merkies ISJ, van Schaik IN, Léger JM, Bril V, van Geloven N, Hartung HP, Lewis RA, Sobue G, Lawo JP, Durn BL, Cornblath DR, De Bleecker JL, Sommer C, Robberecht W, Saarela M, Kamienowski J, Stelmasiak Z, Tackenberg B, Mielke O; PRIMA Trial Investigators and the PATH Study Group.

J Peripher Nerv Syst. 2019 Mar;24(1):48-55. doi: 10.1111/jns.12302. Epub 2019 Feb 15.

6.

Reply.

Mengel D, Dodel R, Tackenberg B.

Muscle Nerve. 2019 Mar;59(3):E23. doi: 10.1002/mus.26406. Epub 2019 Jan 29. No abstract available.

PMID:
30615220
7.

Can we predict cognitive decline after initial diagnosis of multiple sclerosis? Results from the German National early MS cohort (KKNMS).

Johnen A, Bürkner PC, Landmeyer NC, Ambrosius B, Calabrese P, Motte J, Hessler N, Antony G, König IR, Klotz L, Hoshi MM, Aly L, Groppa S, Luessi F, Paul F, Tackenberg B, Bergh FT, Kümpfel T, Tumani H, Stangel M, Weber F, Bayas A, Wildemann B, Heesen C, Zettl UK, Zipp F, Hemmer B, Meuth SG, Gold R, Wiendl H, Salmen A; German Competence Network Multiple Sclerosis (KKNMS).

J Neurol. 2019 Feb;266(2):386-397. doi: 10.1007/s00415-018-9142-y. Epub 2018 Dec 4.

8.

Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation.

Pfeuffer S, Schmidt R, Straeten FA, Pul R, Kleinschnitz C, Wieshuber M, Lee DH, Linker RA, Doerck S, Straeten V, Windhagen S, Pawlitzki M, Aufenberg C, Lang M, Eienbroeker C, Tackenberg B, Limmroth V, Wildemann B, Haas J, Klotz L, Wiendl H, Ruck T, Meuth SG.

J Neurol. 2019 Jan;266(1):165-173. doi: 10.1007/s00415-018-9117-z. Epub 2018 Nov 16.

PMID:
30446966
9.

Costs of illness in chronic inflammatory demyelinating polyneuropathy in Germany.

Mengel D, Fraune L, Sommer N, Stettner M, Reese JP, Dams J, Glynn RJ, Balzer-Geldsetzer M, Dodel R, Tackenberg B.

Muscle Nerve. 2018 Nov;58(5):681-687. doi: 10.1002/mus.26315. Epub 2018 Oct 3.

PMID:
30073683
10.

DNA methylation as a mediator of HLA-DRB1*15:01 and a protective variant in multiple sclerosis.

Kular L, Liu Y, Ruhrmann S, Zheleznyakova G, Marabita F, Gomez-Cabrero D, James T, Ewing E, Lindén M, Górnikiewicz B, Aeinehband S, Stridh P, Link J, Andlauer TFM, Gasperi C, Wiendl H, Zipp F, Gold R, Tackenberg B, Weber F, Hemmer B, Strauch K, Heilmann-Heimbach S, Rawal R, Schminke U, Schmidt CO, Kacprowski T, Franke A, Laudes M, Dilthey AT, Celius EG, Søndergaard HB, Tegnér J, Harbo HF, Oturai AB, Olafsson S, Eggertsson HP, Halldorsson BV, Hjaltason H, Olafsson E, Jonsdottir I, Stefansson K, Olsson T, Piehl F, Ekström TJ, Kockum I, Feinberg AP, Jagodic M.

Nat Commun. 2018 Jun 19;9(1):2397. doi: 10.1038/s41467-018-04732-5.

11.

Incidence and mitigation of gastrointestinal events in patients with relapsing-remitting multiple sclerosis receiving delayed-release dimethyl fumarate: a German phase IV study (TOLERATE).

Gold R, Schlegel E, Elias-Hamp B, Albert C, Schmidt S, Tackenberg B, Xiao J, Schaak T, Salmen HC.

Ther Adv Neurol Disord. 2018 Apr 18;11:1756286418768775. doi: 10.1177/1756286418768775. eCollection 2018.

12.

Treatment choices and neuropsychological symptoms of a large cohort of early MS.

von Bismarck O, Dankowski T, Ambrosius B, Hessler N, Antony G, Ziegler A, Hoshi MM, Aly L, Luessi F, Groppa S, Klotz L, Meuth SG, Tackenberg B, Stoppe M, Then Bergh F, Tumani H, Kümpfel T, Stangel M, Heesen C, Wildemann B, Paul F, Bayas A, Warnke C, Weber F, Linker RA, Ziemann U, Zettl UK, Zipp F, Wiendl H, Hemmer B, Gold R, Salmen A.

Neurol Neuroimmunol Neuroinflamm. 2018 Mar 1;5(3):e446. doi: 10.1212/NXI.0000000000000446. eCollection 2018 May.

13.

Survey of diagnostic and treatment practices for multiple sclerosis (MS) in Europe. Part 2: Progressive MS, paediatric MS, pregnancy and general management.

Fernández O, Delvecchio M, Edan G, Fredrikson S, Giovannoni G, Hartung HP, Havrdova E, Kappos L, Pozzilli C, Soerensen PS, Tackenberg B, Vermersch P, Comi G.

Eur J Neurol. 2018 May;25(5):739-746. doi: 10.1111/ene.13581. Epub 2018 Feb 28.

PMID:
29356206
14.

Acetylcholine Receptor Antibody Titers and Clinical Course after Influenza Vaccination in Patients with Myasthenia Gravis: A Double-Blind Randomized Controlled Trial (ProPATIent-Trial).

Tackenberg B, Schneider M, Blaes F, Eienbröker C, Schade-Brittinger C, Wellek A, Deschauer M, Eickmann M, Klenk HD, Müller HH, Sommer N.

EBioMedicine. 2018 Feb;28:143-150. doi: 10.1016/j.ebiom.2018.01.007. Epub 2018 Jan 10.

15.

Serum titers of autoantibodies against α-synuclein and tau in child- and adulthood.

Kuhn I, Rogosch T, Schindler TI, Tackenberg B, Zemlin M, Maier RF, Dodel R, Kronimus Y.

J Neuroimmunol. 2018 Feb 15;315:33-39. doi: 10.1016/j.jneuroim.2017.12.003. Epub 2017 Dec 11.

PMID:
29306403
16.

Clinical and Demographic Profile of Patients Receiving Fingolimod in Clinical Practice in Germany and the Benefit-Risk Profile of Fingolimod After 1 Year of Treatment: Initial Results From the Observational, Noninterventional Study PANGAEA.

Ziemssen T, Lang M, Tackenberg B, Schmidt S, Albrecht H, Klotz L, Haas J, Lassek C, Medin J, Cornelissen C; PANGAEA study group.

Neurotherapeutics. 2018 Jan;15(1):190-199. doi: 10.1007/s13311-017-0595-y.

17.

Cerebrospinal fluid microRNAs are potential biomarkers of temporal lobe epilepsy and status epilepticus.

Raoof R, Jimenez-Mateos EM, Bauer S, Tackenberg B, Rosenow F, Lang J, Onugoren MD, Hamer H, Huchtemann T, Körtvélyessy P, Connolly NMC, Pfeiffer S, Prehn JHM, Farrell MA, O'Brien DF, Henshall DC, Mooney C.

Sci Rep. 2017 Jun 12;7(1):3328. doi: 10.1038/s41598-017-02969-6.

18.

Minimum clinically important difference analysis confirms the efficacy of IgPro10 in CIDP: the PRIMA trial.

Merkies ISJ, Lawo JP, Edelman JM, De Bleecker JL, Sommer C, Robberecht W, Saarela M, Kamienowski J, Stelmasiak Z, Mielke O, Tackenberg B, Léger JM; PRIMA trial investigators.

J Peripher Nerv Syst. 2017 Jun;22(2):149-152. doi: 10.1111/jns.12204. No abstract available.

19.

Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS.

Fleischer V, Friedrich M, Rezk A, Bühler U, Witsch E, Uphaus T, Bittner S, Groppa S, Tackenberg B, Bar-Or A, Zipp F, Luessi F.

Mult Scler. 2018 Apr;24(5):632-641. doi: 10.1177/1352458517703799. Epub 2017 Apr 24.

PMID:
28436295
20.

Survey of diagnostic and treatment practices for multiple sclerosis in Europe.

Fernández O, Delvecchio M, Edan G, Fredrikson S, Gionvannoni G, Hartung HP, Havrdova E, Kappos L, Pozzilli C, Soerensen PS, Tackenberg B, Vermersch P, Comi G.

Eur J Neurol. 2017 Mar;24(3):516-522. doi: 10.1111/ene.13236. Epub 2017 Jan 31.

PMID:
28139062
21.

Afferent Visual Pathway Affection in Patients with PMP22 Deletion-Related Hereditary Neuropathy with Liability to Pressure Palsies.

Brandt AU, Meinert-Bohn E, Rinnenthal JL, Zimmermann H, Mikolajczak J, Oberwahrenbrock T, Papazoglou S, Pfüller CF, Schinzel J, Tackenberg B, Paul F, Hahn K, Bellmann-Strobl J.

PLoS One. 2016 Oct 17;11(10):e0164617. doi: 10.1371/journal.pone.0164617. eCollection 2016.

22.

Terminal complement activation is increased and associated with disease severity in CIDP.

Quast I, Keller CW, Hiepe F, Tackenberg B, Lünemann JD.

Ann Clin Transl Neurol. 2016 Jul 25;3(9):730-5. doi: 10.1002/acn3.331. eCollection 2016 Sep.

23.

Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab.

Ziemssen T, Gass A, Wuerfel J, Bayas A, Tackenberg B, Limmroth V, Linker R, Mäurer M, Haas J, Stangel M, Meergans M, Harlin O, Hartung HP.

BMC Neurol. 2016 Jul 12;16:98. doi: 10.1186/s12883-016-0625-0.

24.

Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation.

Andlauer TF, Buck D, Antony G, Bayas A, Bechmann L, Berthele A, Chan A, Gasperi C, Gold R, Graetz C, Haas J, Hecker M, Infante-Duarte C, Knop M, Kümpfel T, Limmroth V, Linker RA, Loleit V, Luessi F, Meuth SG, Mühlau M, Nischwitz S, Paul F, Pütz M, Ruck T, Salmen A, Stangel M, Stellmann JP, Stürner KH, Tackenberg B, Then Bergh F, Tumani H, Warnke C, Weber F, Wiendl H, Wildemann B, Zettl UK, Ziemann U, Zipp F, Arloth J, Weber P, Radivojkov-Blagojevic M, Scheinhardt MO, Dankowski T, Bettecken T, Lichtner P, Czamara D, Carrillo-Roa T, Binder EB, Berger K, Bertram L, Franke A, Gieger C, Herms S, Homuth G, Ising M, Jöckel KH, Kacprowski T, Kloiber S, Laudes M, Lieb W, Lill CM, Lucae S, Meitinger T, Moebus S, Müller-Nurasyid M, Nöthen MM, Petersmann A, Rawal R, Schminke U, Strauch K, Völzke H, Waldenberger M, Wellmann J, Porcu E, Mulas A, Pitzalis M, Sidore C, Zara I, Cucca F, Zoledziewska M, Ziegler A, Hemmer B, Müller-Myhsok B.

Sci Adv. 2016 Jun 17;2(6):e1501678. doi: 10.1126/sciadv.1501678. eCollection 2016 Jun.

25.

[Myasthenia gravis].

Schodrowski J, Seipelt M, Adibi-Sedeh I, Eienbröker C, Tackenberg B.

Internist (Berl). 2016 Apr;57(4):349-61. doi: 10.1007/s00108-016-0035-9. German.

PMID:
27000188
26.

[Monitoring of blood parameters under course-modified MS therapy : Substance-specific relevance and current recommendations for action].

Klotz L, Berthele A, Brück W, Chan A, Flachenecker P, Gold R, Haghikia A, Hellwig K, Hemmer B, Hohlfeld R, Korn T, Kümpfel T, Lang M, Limmroth V, Linker RA, Meier U, Meuth SG, Paul F, Salmen A, Stangel M, Tackenberg B, Tumani H, Warnke C, Weber MS, Ziemssen T, Zipp F, Wiendl H.

Nervenarzt. 2016 Jun;87(6):645-59. doi: 10.1007/s00115-016-0077-1. Review. German.

PMID:
26927677
27.

Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society.

Melzer N, Ruck T, Fuhr P, Gold R, Hohlfeld R, Marx A, Melms A, Tackenberg B, Schalke B, Schneider-Gold C, Zimprich F, Meuth SG, Wiendl H.

J Neurol. 2016 Aug;263(8):1473-94. doi: 10.1007/s00415-016-8045-z. Epub 2016 Feb 17. Review.

28.

Increased Frequency of T Follicular Helper Cells and Elevated Interleukin-27 Plasma Levels in Patients with Pemphigus.

Hennerici T, Pollmann R, Schmidt T, Seipelt M, Tackenberg B, Möbs C, Ghoreschi K, Hertl M, Eming R.

PLoS One. 2016 Feb 12;11(2):e0148919. doi: 10.1371/journal.pone.0148919. eCollection 2016.

29.

Whole-body vibration therapy in intensive care patients: A feasibility and safety study.

Boeselt T, Nell C, Kehr K, Holland A, Dresel M, Greulich T, Tackenberg B, Kenn K, Boeder J, Klapdor B, Kirschbaum A, Vogelmeier C, Alter P, Koczulla AR.

J Rehabil Med. 2016 Mar;48(3):316-21. doi: 10.2340/16501977-2052.

30.

36 Months Pangaea: A 5-Year Non-Interventional Study of Safety, Efficacy and Pharmacoeconomic Data for Fingolimod Patients In Daily Clinical Practice.

Ziemssen T, Albrecht H, Haas J, Klotz L, Lang M, Lassek C, Schmidt S, Tackenberg B, Cornelissen C.

Value Health. 2015 Nov;18(7):A749. doi: 10.1016/j.jval.2015.09.2894. Epub 2015 Oct 20. No abstract available.

31.

Successful Replication of GWAS Hits for Multiple Sclerosis in 10,000 Germans Using the Exome Array.

Dankowski T, Buck D, Andlauer TF, Antony G, Bayas A, Bechmann L, Berthele A, Bettecken T, Chan A, Franke A, Gold R, Graetz C, Haas J, Hecker M, Herms S, Infante-Duarte C, Jöckel KH, Kieseier BC, Knier B, Knop M, Kümpfel T, Lichtner P, Lieb W, Lill CM, Limmroth V, Linker RA, Loleit V, Meuth SG, Moebus S, Müller-Myhsok B, Nischwitz S, Nöthen MM, Paul F, Pütz M, Ruck T, Salmen A, Stangel M, Stellmann JP, Strauch K, Stürner KH, Tackenberg B, Then Bergh F, Tumani H, Waldenberger M, Weber F, Wiendl H, Wildemann B, Zettl UK, Ziemann U, Zipp F, Hemmer B, Ziegler A; German Competence Network for Multiple Sclerosis (KKNMS).

Genet Epidemiol. 2015 Dec;39(8):601-8. doi: 10.1002/gepi.21933. Epub 2015 Oct 26.

PMID:
26497834
32.

Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity.

Quast I, Keller CW, Maurer MA, Giddens JP, Tackenberg B, Wang LX, Münz C, Nimmerjahn F, Dalakas MC, Lünemann JD.

J Clin Invest. 2015 Nov 2;125(11):4160-70. doi: 10.1172/JCI82695. Epub 2015 Oct 5.

33.

PML risk stratification using anti-JCV antibody index and L-selectin.

Schwab N, Schneider-Hohendorf T, Pignolet B, Spadaro M, Görlich D, Meinl I, Windhagen S, Tackenberg B, Breuer J, Cantó E, Kümpfel T, Hohlfeld R, Siffrin V, Luessi F, Posevitz-Fejfár A, Montalban X, Meuth SG, Zipp F, Gold R, Du Pasquier RA, Kleinschnitz C, Jacobi A, Comabella M, Bertolotto A, Brassat D, Wiendl H.

Mult Scler. 2016 Jul;22(8):1048-60. doi: 10.1177/1352458515607651. Epub 2015 Oct 2.

PMID:
26432858
34.

Deregulated Fcγ receptor expression in patients with CIDP.

Quast I, Cueni F, Nimmerjahn F, Tackenberg B, Lünemann JD.

Neurol Neuroimmunol Neuroinflamm. 2015 Aug 20;2(5):e148. doi: 10.1212/NXI.0000000000000148. eCollection 2015 Oct.

35.

[Current aspects of therapy conversion for multiple sclerosis].

Kolber P, Luessi F, Meuth SG, Klotz L, Korn T, Trebst C, Tackenberg B, Kieseier B, Kümpfel T, Fleischer V, Tumani H, Wildemann B, Lang M, Flachenecker P, Meier U, Brück W, Limmroth V, Haghikia A, Hartung HP, Stangel M, Hohlfeld R, Hemmer B, Gold R, Wiendl H, Zipp F.

Nervenarzt. 2015 Oct;86(10):1236-47. doi: 10.1007/s00115-015-4368-8. Review. German.

PMID:
26269289
36.

Measuring Compounds in Exhaled Air to Detect Alzheimer's Disease and Parkinson's Disease.

Bach JP, Gold M, Mengel D, Hattesohl A, Lubbe D, Schmid S, Tackenberg B, Rieke J, Maddula S, Baumbach JI, Nell C, Boeselt T, Michelis J, Alferink J, Heneka M, Oertel W, Jessen F, Janciauskiene S, Vogelmeier C, Dodel R, Koczulla AR.

PLoS One. 2015 Jul 13;10(7):e0132227. doi: 10.1371/journal.pone.0132227. eCollection 2015.

37.

[Pegylated interferon beta 1a. A new therapy option for treatment of relapsing-remitting multiple sclerosis].

Leussink VI, Warnke C, Tackenberg B, Wiendl H, Kieseier BC.

Nervenarzt. 2015 Apr;86(4):483-90. doi: 10.1007/s00115-015-4287-8. German.

PMID:
25833401
38.

[Prognostic and predictively relevant factors for multiple sclerosis].

Tackenberg B, Schneider-Hohendorf T, Müller A, Schodrowski J, Wiendl H.

Nervenarzt. 2014 Oct;85(10):1255-62. doi: 10.1007/s00115-014-4062-2. Review. German.

PMID:
25252736
39.

MK2 and Fas receptor contribute to the severity of CNS demyelination.

Tietz SM, Hofmann R, Thomas T, Tackenberg B, Gaestel M, Berghoff M.

PLoS One. 2014 Jun 25;9(6):e100363. doi: 10.1371/journal.pone.0100363. eCollection 2014.

40.

Chronic valproate or levetiracetam treatment does not influence cytokine levels in humans.

Guenther S, Bauer S, Hagge M, Knake S, Olmes DG, Tackenberg B, Rosenow F, Hamer HM.

Seizure. 2014 Sep;23(8):666-9. doi: 10.1016/j.seizure.2014.04.011. Epub 2014 Apr 29.

41.

Predictors for multiple sclerosis relapses after switching from natalizumab to fingolimod.

Hoepner R, Havla J, Eienbröker C, Tackenberg B, Hellwig K, Meinl I, Hohlfeld R, Gold R, Kümpfel T, Kleiter I.

Mult Scler. 2014 Nov;20(13):1714-20. doi: 10.1177/1352458514533398. Epub 2014 May 19.

PMID:
24842961
42.

Intravenous immunoglobulin maintenance treatment in myasthenia gravis: a randomized, controlled trial sample size simulation.

Eienbröker C, Seitz F, Spengler A, Kurz H, Seipelt M, Sommer N, Oertel WH, Timmesfeld N, Tackenberg B.

Muscle Nerve. 2014 Dec;50(6):999-1004. doi: 10.1002/mus.24259. Epub 2014 Oct 30.

PMID:
24710856
43.

Preference-based Health status in a German outpatient cohort with multiple sclerosis.

Reese JP, Wienemann G, John A, Linnemann A, Balzer-Geldsetzer M, Mueller UO, Eienbröker C, Tackenberg B, Dodel R.

Health Qual Life Outcomes. 2013 Oct 3;11:162. doi: 10.1186/1477-7525-11-162.

44.

Efficacy and safety of Privigen(®) in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study).

Léger JM, De Bleecker JL, Sommer C, Robberecht W, Saarela M, Kamienowski J, Stelmasiak Z, Mielke O, Tackenberg B, Shebl A, Bauhofer A, Zenker O, Merkies IS; PRIMA study investigators.

J Peripher Nerv Syst. 2013 Jun;18(2):130-40. doi: 10.1111/jns5.12017.

45.

Levetiracetam but not valproate inhibits function of CD8+ T lymphocytes.

Li G, Nowak M, Bauer S, Schlegel K, Stei S, Allenhöfer L, Waschbisch A, Tackenberg B, Höllerhage M, Höglinger GU, Wegner S, Wang X, Oertel WH, Rosenow F, Hamer HM.

Seizure. 2013 Jul;22(6):462-6. doi: 10.1016/j.seizure.2013.03.006. Epub 2013 Apr 29.

46.

Cerebrospinal fluid concentrations of ghrelin in patients with multiple sclerosis.

Unger MM, Oertel WH, Tackenberg B.

Neuro Endocrinol Lett. 2013;34(1):14-7.

PMID:
23524619
47.

Myasthenia gravis: analysis of serum autoantibody reactivities to 1827 potential human autoantigens by protein macroarrays.

Becker A, Ludwig N, Keller A, Tackenberg B, Eienbröker C, Oertel WH, Fassbender K, Meese E, Ruprecht K.

PLoS One. 2013;8(3):e58095. doi: 10.1371/journal.pone.0058095. Epub 2013 Mar 4.

48.

Natalizumab treatment decreases serum IgM and IgG levels in multiple sclerosis patients.

Selter RC, Biberacher V, Grummel V, Buck D, Eienbröker C, Oertel WH, Berthele A, Tackenberg B, Hemmer B.

Mult Scler. 2013 Oct;19(11):1454-61. doi: 10.1177/1352458513477229. Epub 2013 Feb 25.

PMID:
23439578
49.

Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis.

Havla J, Tackenberg B, Hellwig K, Meinl I, Krumbholz M, Seitz F, Eienbröker C, Gold R, Hohlfeld R, Kleiter I, Kümpfel T.

J Neurol. 2013 May;260(5):1382-7. doi: 10.1007/s00415-012-6808-8. Epub 2012 Dec 25.

PMID:
23266894
50.

IL-17A secretion by CD8+ T cells supports Th17-mediated autoimmune encephalomyelitis.

Huber M, Heink S, Pagenstecher A, Reinhard K, Ritter J, Visekruna A, Guralnik A, Bollig N, Jeltsch K, Heinemann C, Wittmann E, Buch T, Prazeres da Costa O, Brüstle A, Brenner D, Mak TW, Mittrücker HW, Tackenberg B, Kamradt T, Lohoff M.

J Clin Invest. 2013 Jan;123(1):247-60. doi: 10.1172/JCI63681. Epub 2012 Dec 10.

Supplemental Content

Loading ...
Support Center